Objective To research the changes of the serum calmodulin (CaM) activity and its response to the oral hypoglycemic agent (OHA) in patients with type 2 diabetes mellitus (DM2).

• 目的探讨2型糖尿病（DM2）患者血清钙调素（CaM）活性的变化及其对治疗的反应。